GM-CSF/Ipilimumab combination extends melanoma survival.
In a phase II trial, combining the granulocyte-macrophage colony-stimulating factor sargramostin and the CTLA-4 inhibitor ipilimumab prolonged survival and caused fewer serious side effects in patients with metastatic melanoma compared with ipilimumab alone.